Hyperfine (HYPR) delivered the strongest quarter in its history. On the normalized figures it lost $0.07 per share against a consensus of -$0.08, a 12.5% beat. Earnings improved 36.4% year over year on revenue of $5.96 million, which rose 73.4%. The GAAP net loss was $0.06 per share versus $0.14 a year ago. That GAAP figure was helped by a $1.5 million non-cash gain on warrant liabilities, compared with a $2.3 million warrant loss in the prior-year quarter, so the normalized comparison is the cleaner read. The central tension is that management called this the start of "the new Hyperfine" yet left full-year revenue guidance unchanged. Meanwhile, the stock sits near 52-week lows with a fresh shelf registration on the way.
The quality of the quarter holds up well beneath the warrant noise. Revenue jumped 53% sequentially from $3.9 million, after two flat quarters at that level. Device sales nearly doubled to $5.2 million. Unit volume climbed steadily from 10 systems in Q1 to 12 in Q2 and 14 in Q3. Gross margin reached a record 56.7%, up from 50.7% in each of the first two quarters. Total operating expenses actually dipped 1% year over year. The result was the narrowest operating loss in company history, $7.3 million, down 14% sequentially. Net cash burn fell to $5.6 million from $7.9 million in Q2 and $8.8 million in Q1. For the first time, quarterly revenue exceeded cash burn. This is genuine operating leverage, not an accounting artifact.
The call added texture on demand. Management described follow-on orders from health systems and integrated delivery networks as now a meaningful revenue component. That is a step up from a single IDN expansion in Q1 and the first national IDN placement in July. The company also raised the low end of its full-year gross margin guidance, which now stands at 52.5% to 55% versus 50% to 55% previously. That was the only guided metric that moved, and nothing was cut. Outside the U.S., Model 2 is already selling in four international markets one quarter after launch, and a new exclusive distributor covers Kuwait and the UAE. On the regulatory front, Contrast PMR enrollment is complete and the 510(k) submission remains on track for year-end. Management expects clearance around mid-2027, which would open office-based reimbursement under CPT 70553. That is the most concrete medium-term catalyst. The new brain wellness and longevity vertical is a narrative extension rather than a near-term driver, since management does not expect revenue from it before 2028.
Bears have legitimate ammunition, starting with guidance. Revenue guidance of $20 million to $22 million is unchanged from all three prior calls, even though nine-month revenue already totals $13.8 million. The low end implies Q4 revenue of roughly $6.2 million, essentially flat with Q3. Management pointed to lumpy capital-equipment timing, national IDNs that need two to three quarters before follow-on orders arrive, and a tough Q4 comparison that included a one-time multi-unit upgrade. Those are reasonable explanations, but they also signal that Q3 may not be a clean run rate. Management also cautioned that Q3's record ASP may not fully recur and offered no 2027 margin commitment. Modest commercial investment planned for 2027 could slow the expense leverage that defined this quarter.
The balance sheet is the other overhang. Cash fell to $37.9 million from $43.5 million in Q2, and the company raised no money during the quarter. Year to date, however, it has drawn on $13.6 million of debt and $11.4 million of at-the-market equity. Weighted shares rose to 106 million from 79 million a year ago. Management also plans a new $150 million universal shelf that includes a $50 million ATM program. With the stock at $0.72, any further equity issuance would be meaningfully dilutive.
The market has not rewarded the operating progress. Shares are down 25.8% since the open after the August report and trade 35.7% below their $1.12 200-day moving average. The stock set a 52-week low of $0.67 on November 3 and entered the report just 7.8% above it, after a fade from an October high of $1.05. Price and AVWAP trend readings remain negative. Investor sentiment improved modestly, from 0.12 to 0.20, and remains mildly positive. That suggests expectations firmed somewhat without becoming enthusiastic.
The bottom line is that Hyperfine produced the evidence of operating leverage that skeptics have been waiting for: record revenue, record margin, flat expenses and burn below revenue. However, reaffirmed guidance implies Q3 may be a high-water mark for now rather than a new floor. Upcoming financing capacity and a sub-$1 share price keep dilution risk front and center. The year-end Contrast PMR submission and whether Q4 lands above the guidance floor are the next tests of whether this quarter marks a durable inflection.